News from us and our partners

Tags

Topics

0 results

News
31 May, 2017
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
News
22 May, 2017
Graziano Seghezzi est promu Managing Partner de Sofinnova Partners
News
22 May, 2017
Graziano Seghezzi appointed Managing Partner of Sofinnova Partners
News
17 May, 2017
ProQR Announces Results for the First Quarter of 2017
News
17 May, 2017
NOXXON PHARMA ANNOUNCES COLLABORATION WITH NATIONAL CENTER FOR TUMOR DISEASES IN HEIDELBERG FOR NOX-A12/KEYTRUDA® PHASE 1/2 COMBINATION TRIAL
News
12 May, 2017
Shockwave Medical Appoints Doug Godshall as President and CEO
News
9 May, 2017
Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain in Ireland
News
9 May, 2017
RefleXion Medical appoints Todd Powell as president and CEO
News
5 May, 2017
Hookipa Biotech presents positive data from Phase 1 first-in-human trial of vaccine against cytomegalovirus
News
11 April, 2017
Mission Therapeutics and University of Oxford Awarded Research Grant from the Michael J. Fox Foundation
News
4 April, 2017
Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer
News
28 March, 2017
Antoine Papiernik appointed Chairman of Sofinnova Partners
News
27 March, 2017
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
News
14 March, 2017
Sofinnova Partners announces the successful IPO of Avantium, a front runner in renewable chemistry, which raises €103 M on Euronext
News
13 March, 2017
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
News
8 March, 2017
Breath Therapeutics Raises EUR 43.5 Million in Series A Financing

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

Graziano Seghezzi est promu Managing Partner de Sofinnova Partners

Graziano Seghezzi appointed Managing Partner of Sofinnova Partners

ProQR Announces Results for the First Quarter of 2017

NOXXON PHARMA ANNOUNCES COLLABORATION WITH NATIONAL CENTER FOR TUMOR DISEASES IN HEIDELBERG FOR NOX-A12/KEYTRUDA® PHASE 1/2 COMBINATION TRIAL

Shockwave Medical Appoints Doug Godshall as President and CEO

Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain in Ireland

RefleXion Medical appoints Todd Powell as president and CEO

Hookipa Biotech presents positive data from Phase 1 first-in-human trial of vaccine against cytomegalovirus

Mission Therapeutics and University of Oxford Awarded Research Grant from the Michael J. Fox Foundation

Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer

Antoine Papiernik appointed Chairman of Sofinnova Partners

ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

Sofinnova Partners announces the successful IPO of Avantium, a front runner in renewable chemistry, which raises €103 M on Euronext

ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART

Breath Therapeutics Raises EUR 43.5 Million in Series A Financing